Company Encyclopedia
View More
name
UNITED LAB
03933.HK
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules. It also provides intermediate products, such as 6-aminopenicillanic acid, tert-octylammonium clavulanate, anhydrous sodium carbonate sterile, and penicillin G potassium first crystal.
1.390 T
03933.HKMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking20/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE21.05%A
    • Profit Margin21.72%A
    • Gross Margin52.19%B
  • Growth ScoreC
    • Revenue YoY0.81%C
    • Net Profit YoY5.47%C
    • Total Assets YoY31.35%A
    • Net Assets YoY17.16%A
  • Cash ScoreC
    • Cash Flow Margin460.45%C
    • OCF YoY0.81%C
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreC
    • Gearing Ratio46.96%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | UNITED LAB continues to decline with increasing volume, is pharmaceutical capital becoming more cautious?

    United Lab (3933.HK) showed weakness on the 16th, with a significant increase in trading volume throughout the day but no signs of capital support, leading to a breach of the low-level consolidation. Overall confidence in the pharmaceutical sector is insufficient, with policy pressures and unlocks occurring simultaneously, resulting in extremely cautious market sentiment. At the opening, funds quickly fled, and buying pressure shifted, increasing the defensive nature of the sector. On the news front, the "pressure from volume-based procurement price reductions" continues to ferment, with profits at the distribution end being continuously compressed, leading industry leaders to adopt a contraction strategy. The feedback from medical insurance policies has been poor, raising market concerns about short-term profit declines, and the company currently lacks new positive stimuli, prompting funds to choose defensive strategies. Technically, multiple moving averages are pressing down, with the stock price repeatedly testing the recent low of HKD 4.92. There is significant divergence between bulls and bears during the session, with the MACD green bar area expanding, exacerbating weak negative feedback. If trading volume continues to increase without halting the decline, the main force has not completed the chip turnover, and the defense line is loosening. Attention should be paid to medical insurance policies and intraday capital fluctuations, and a wait-and-see strategy is advisable during this phase. Continuous volume increases should be monitored, as breaching the low point poses risks for short-term declines

    Technical Forecast·
    HK
    03933
    -0.09%
    Technical Forecast·
    HK
    03933
    -0.09%

    UNITED LAB: Levofloxacin and Moxifloxacin Hydrochloride Eye Drops have passed the market approval

    UNITED LAB announced that its subsidiary's application for levofloxacin and moxifloxacin hydrochloride eye drops has been approved for listing by the National Medical Products Administration of China. These two drugs are third-generation and fourth-generation fluoroquinolone antibiotics, respectively, suitable for the treatment of various eye infections, and have been included in the national medical insurance catalog

    AASTOCKS·
    HK
    03933
    -0.09%
    AASTOCKS·
    HK
    03933
    -0.09%

    Morning Trend | UNITED LAB (3933.HK) shows weakness in intraday trading, is the marginal signal of sector sentiment worth tracking?

    UNITED LAB (3933.HK) faced downward pressure yesterday, with funds tentatively flowing out after the opening, and multiple attempts to hold the HKD 8.5 range during the day. The company has had no new positive news for three days, and the sentiment in the pharmaceutical sector is low, with scattered buying. The MACD shows a slight death cross and is under pressure from moving averages. Attention should be paid to whether there is an unusual large inflow of funds at support points. If support is lost in the short term, there may be a risk of structural overselling, and any unusual movements should be verified in conjunction with the overall sentiment of the sector

    Technical Forecast·
    HK
    03933
    -0.09%
    Technical Forecast·
    HK
    03933
    -0.09%
    © 2025 Longbridge｜Disclaimer